{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-019151","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.618433+00:00","generated_at":"2026-05-21T04:31:56.355985+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Therapeutics Q1 net loss $9.6M; Belapectin shows liver stiffness reduction at EASL","bullets":["Net loss for Q1 2025 was $9.6M ($0.15 per share) vs $11.5M ($0.19) in Q1 2024.","Cash and equivalents $7.4M as of March 31, 2025; additional $11M available under lines of credit; runway through August 2025.","Belapectin 2 mg/kg showed statistically significant reduction in liver stiffness from baseline at weeks 26, 52, 78 (p<0.02).","Proportion of patients with >30% worsening in liver stiffness: 11.7% for belapectin vs 23.9% for placebo (51% fewer, p=0.03).","Data presented at EASL May 2025; Fast Track Designation for belapectin in MASH cirrhosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-019151","json":"https://secwatch.observer/filing/0001140361-25-019151.json","markdown":"https://secwatch.observer/filing/0001140361-25-019151.md","text":"https://secwatch.observer/filing/0001140361-25-019151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/0001140361-25-019151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/ef20048561_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:31:56.355985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}